DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women

NCT ID: NCT03227458

Last Updated: 2024-12-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 152 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-02-12
• Study Completion Date: 2024-06-19

Brief Summary

To determine whether the musculoskeletal adaptations to bone-loading exercise can be significantly augmented in older women (aged 60-85) with low bone mass (osteopenia; T-scores <-1.0 and >-2.5) or moderate osteoporosis (T-scores < -2.5 and >= -3.0) and by restoring serum DHEAS to young adult levels by oral DHEA replacement.

Detailed Description

This will be the first study to measure changes in areal bone mineral density (aBMD) and fat-free mass (FFM) in response to dehydroepiandrosterone (DHEA) alone and combined with exercise in postmenopausal women. The body of evidence from carefully executed Randomized Controlled Studies (RCTs) provides support for DHEA therapy to increase aBMD and FFM in older women. Less is known about whether DHEA therapy enhances the effects of exercise on the aging musculoskeletal system when an appropriate mechanical stimulus is applied.

Conditions

Low Bone Mass; Osteoporosis, Postmenopausal

Keywords

areal bone mineral density; dehydroepiandrosterone (DHEA); postmenopause; exercise; sex hormones

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: TRIPLE

Study Groups

Exercise and DHEA

1 study pill containing 50 mg of DHEA daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.

Group Type: ACTIVE_COMPARATOR

DHEA

Intervention Type: OTHER

Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.

Exercise

Intervention Type: BEHAVIORAL

bone-loading exercise on 3 days per week for 38 weeks

Exercise and Placebo

1 study pill containing placebo daily for 36 weeks and supervised bone-loading exercise on 3 days per week for 36 weeks.

Group Type: ACTIVE_COMPARATOR

Placebo

Intervention Type: OTHER

Participants will take placebo daily for 36 weeks.

Exercise

Intervention Type: BEHAVIORAL

bone-loading exercise on 3 days per week for 38 weeks

DHEA only

1 study pill containing 50 mg of DHEA daily for 36 weeks

Group Type: ACTIVE_COMPARATOR

DHEA

Intervention Type: OTHER

Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.

Interventions

DHEA

Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.

Intervention Type: OTHER

Placebo

Participants will take placebo daily for 36 weeks.

Intervention Type: OTHER

Exercise

bone-loading exercise on 3 days per week for 38 weeks

Intervention Type: BEHAVIORAL

Other Intervention Names

DHEA therapy; bone-loading exercise

Eligibility Criteria

Inclusion Criteria

• non-frail, as determined by short physical performance battery (SPPB) score > 9 (0-12 scale);
• 5 years or longer since menopause (defined as last menstrual period);
• willing to participate in a 36-week exercise program that will start at a moderate intensity and gradually progress to a higher intensity;
• willing to be randomized to an exercise or a no-exercise arm of the study;
• willing to take DHEA (50mg/d) or a placebo pill daily and remain blinded for up to 36 weeks;
• not performing resistance exercise training or high impact weight-bearing exercise (e.g., jogging) ≥ 2 days per week in the past 6 months;
• ambulatory without assistive devices;
• serum DHEAS < 140 μg/dL (3.8 μmol/L);
• low bone mass or moderate osteoporosis defined as lumbar spine or proximal hip aBMD t-scores < -1.0 and > = -3.0;
• refusal of standard osteoporosis treatment in women with moderate osteoporosis (BMD t-scores >=-3.0 and =< 2.5).
• evidence of a negative (no findings suspicious for breast cancer) mammogram within the past 12 months;
• planning to reside in the Denver area for the duration of the study
• normal cognitive function, as determined by a Mini-Cog score > = 4

Exclusion Criteria

• history of hospitalization for Corona Virus Disease-19 (COVID-19)
• does not meet Centers for Disease Control and Prevention (CDC) recommendations for home isolation because has had a positive severe acute respiratory syndrome corona virus-2 (SARS-COV-2) test less than 10 days before study entry; or has had fever within the past 3 days and respiratory symptoms have not improved; or symptoms first appeared less than 10 days before study entry
• uncontrolled hypertension defined as resting systolic blood pressure (sBP) >150 mmHg or diastolic blood pressure (dBP) >90 mmHg; participants who do not meet these criteria at first screening will be re-evaluated, including follow-up evaluation by their Primary Care Physician (PCP) with initiation or adjustment of anti-hypertensive medications;
• diagnosed ischemic heart disease or indicators of unstable ischemic heart disease (e.g., angina, ST segment depression) or arrhythmias at rest or during the Gated Exercise Test (GXT) without negative follow-up evaluation will be cause for exclusion; follow-up evaluation must include diagnostic testing (e.g., thallium stress test) with interpretation by a cardiologist;
• diagnosis of heart failure, clinically significant aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia.
• pulmonary disease requiring use of oral steroids within the previous 6 months or the use of supplemental oxygen ≥ 4 liters with physical exertion
• orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly limit the ability to perform moderate to high intensity resistance exercise (e.g., unable to be properly positioned in exercise equipment or to have severely restricted range of motion even after modifications have been made)
• hip fracture, hip or knee replacement, or spinal surgery in the past 6 months;
• undergoing physical therapy involving the lower extremities;
• hematocrit (HCT) > 54%;
• thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) < 0.4 or > 10.0 microunits/mL;, without signs or symptoms of clinical hypo- or hyperthyroidism. Volunteers with abnormal TSH values will be re-considered for participation in the study after follow-up evaluation by their PCP with initiation or adjustment of thyroid hormone replacement;
• acute liver disease indicated by liver function tests (alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase) ≥ 1.5 times the upper limits of normal;
• estimated glomerular filtration rate (eGFR) < 45, using the Modification of Diet in Renal Disease (MDRD) equation (Levey et al, Annals Inter Med, 1999; Munter et al, Clin J Am Soc Nephrology, 2009);
• poorly controlled diabetes mellitus based on HbA1c > 8.5%, or use of insulin;
• fasted serum triglycerides > 400 mg/dL;
• serum 25-hydroxy vitamin D <20 ng/mL; volunteers will be re-considered for participation in the study after follow-up evaluation by their PCP with initiation or adjustment of vitamin D supplementation per the study's vitamin D repletion protocol.
• use of DHEA supplementation or sex hormones in the past 6 months. Use of prescription low dose vaginal estrogen creams (Premarin or Estrace) 3 days per week will not be exclusionary.
• use in the past 6 months of any medications known to alter bone metabolism (e.g., oral glucocorticoids, bone anti-resorptive agents);
• documented history of cognitive impairment or dementia, or Mini-Cog < 4;
• current smoker;
• personal history of breast, ovarian, metastatic endometrial, or cervical cancer;
• any cancer requiring treatment in the past 3 years except non-melanoma skin cancers;
• un-diagnosed vaginal bleeding;
• women who, in the judgment of the study physician, appear incapable of safely participating in the exercise (e.g., neuromuscular/musculoskeletal impairment)
• use of insulin;
• lumbar spine, total hip, or femoral neck aBMD t-scores < -3.0;
• secondary osteoporosis

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

National Institute on Aging (NIA)

NIH

Sponsor Role: collaborator

University of Colorado, Denver

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Catherine Jankowski, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Colorado, Denver

Locations

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States

Countries

United States

Other Identifiers

5R01AG053489-05

Identifier Type: NIH

Identifier Source: secondary_id

View Link

16-2427

Identifier Type: -

Identifier Source: org_study_id